Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $49
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Eddie Hickman maintains a Buy rating on Tarsus Pharmaceuticals (NASDAQ:TARS) and raises the price target from $46 to $49.
September 11, 2023 | 1:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst maintains a Buy rating on Tarsus Pharmaceuticals and raises the price target from $46 to $49.
The news directly pertains to Tarsus Pharmaceuticals. The maintained Buy rating and increased price target by Guggenheim analyst Eddie Hickman indicates a positive outlook for the company, which could potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100